Why They Are Used Together CJC-1295 provides the sustained, slow-release component while Ipamorelin provides the targeted, immediate GH pulse
While pharmacotherapies for treatment of obesity prior to GLP-1RAs have had limited impact on cardiovascular outcomes, bariatric surgical procedures have shown long-standing, durable outcomes [7]
With major vascular occlusions, there was, at the periphery, the leading role of the rapid heart disturbances, and thereby, heart, lung, liver, kidney and gastrointestinal lesions, inferior and superior vena caval congestion, azygos vein failure, portal and caval hypertension and aortal hypotension occur [14,15,16,17,18,19,20]
Moreover, efpeglenatide therapy reduced the risk of CV disease by about 27% compared to the placebo in the Effect of Efpeglenatide on Cardiovascular Outcomes (AMPLITUDE-O) study [51]